Ondine Biomedical Inc.

AIM:OBI Stock Report

Market Cap: UK£22.9m

Ondine Biomedical Valuation

Is OBI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of OBI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate OBI's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate OBI's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for OBI?

Key metric: As OBI is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for OBI. This is calculated by dividing OBI's market cap by their current revenue.
What is OBI's PS Ratio?
PS Ratio24.5x
SalesCA$1.63m
Market CapCA$40.07m

Price to Sales Ratio vs Peers

How does OBI's PS Ratio compare to its peers?

The above table shows the PS ratio for OBI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average10.4x
POLX Polarean Imaging
12.5x57.3%UK£18.7m
BELL Belluscura
12x151.8%UK£17.3m
AGL ANGLE
16.7x51.5%UK£33.9m
IHC Inspiration Healthcare Group
0.4x13.6%UK£14.6m
OBI Ondine Biomedical
24.5x66.0%UK£22.9m

Price-To-Sales vs Peers: OBI is expensive based on its Price-To-Sales Ratio (24.5x) compared to the peer average (10.4x).

Price to Sales Ratio vs Industry

How does OBI's PS Ratio compare vs other companies in the GB Medical Equipment Industry?

4 CompaniesPrice / SalesEstimated GrowthMarket Cap
SPEC INSPECS Group
0.3x5.5%US$64.34m
YGEN Yourgene Health
0.6xn/aUS$20.48m
IHC Inspiration Healthcare Group
0.4x13.6%US$18.26m
SUN Surgical Innovations Group
0.4xn/aUS$6.43m
No more companies available in this PS range
OBI 24.5xIndustry Avg. 3.0xNo. of Companies4PS02.44.87.29.612+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: OBI is expensive based on its Price-To-Sales Ratio (24.5x) compared to the UK Medical Equipment industry average (3x).

Price to Sales Ratio vs Fair Ratio

What is OBI's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

OBI PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio24.5x
Fair PS Ratio14x

Price-To-Sales vs Fair Ratio: OBI is expensive based on its Price-To-Sales Ratio (24.5x) compared to the estimated Fair Price-To-Sales Ratio (14x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst OBI forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUK£0.083
UK£0.60
+627.3%
8.3%UK£0.65UK£0.55n/a2
Nov ’25UK£0.087
UK£0.57
+557.1%
13.0%UK£0.65UK£0.50n/a2
Oct ’25UK£0.068
UK£0.55
+714.8%
18.2%UK£0.65UK£0.45n/a2
Sep ’25UK£0.07
UK£0.55
+685.7%
18.2%UK£0.65UK£0.45n/a2
Aug ’25UK£0.083
UK£0.55
+566.7%
18.2%UK£0.65UK£0.45n/a2
Jul ’25UK£0.077
UK£0.55
+609.7%
18.2%UK£0.65UK£0.45n/a2
Jun ’25UK£0.07
UK£0.55
+685.7%
18.2%UK£0.65UK£0.45n/a2
May ’25UK£0.051
UK£0.55
+973.2%
18.2%UK£0.65UK£0.45n/a2
Apr ’25UK£0.092
UK£0.57
+521.6%
13.0%UK£0.65UK£0.50n/a2
Jan ’25UK£0.087
UK£0.57
+557.1%
13.0%UK£0.65UK£0.50n/a2
Dec ’24UK£0.088
UK£0.57
+549.7%
13.0%UK£0.65UK£0.50n/a2
Nov ’24UK£0.12
UK£0.57
+400.0%
13.0%UK£0.65UK£0.50UK£0.0872
Oct ’24UK£0.092
UK£0.57
+521.6%
13.0%UK£0.65UK£0.50UK£0.0682
Sep ’24UK£0.095
UK£0.57
+505.3%
13.0%UK£0.65UK£0.50UK£0.072
Aug ’24UK£0.16
UK£0.57
+259.4%
13.0%UK£0.65UK£0.50UK£0.0832
Jul ’24UK£0.13
UK£0.57
+360.0%
13.0%UK£0.65UK£0.50UK£0.0772
Jun ’24UK£0.15
UK£0.57
+271.0%
13.0%UK£0.65UK£0.50UK£0.072
May ’24UK£0.19
UK£0.63
+228.9%
4.0%UK£0.65UK£0.60UK£0.0512
Apr ’24UK£0.16
UK£0.63
+296.8%
4.0%UK£0.65UK£0.60UK£0.0922
Mar ’24UK£0.17
UK£0.95
+458.8%
48.4%UK£1.60UK£0.60UK£0.0983
Feb ’24UK£0.20
UK£0.95
+375.0%
48.4%UK£1.60UK£0.60UK£0.103
Jan ’24UK£0.20
UK£0.95
+363.4%
48.4%UK£1.60UK£0.60UK£0.0873
Dec ’23UK£0.24
UK£0.95
+287.8%
48.4%UK£1.60UK£0.60UK£0.0883
Nov ’23UK£0.25
UK£0.95
+276.2%
48.4%UK£1.60UK£0.60UK£0.123

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Elevance Health

US$93.4b

Operates as a health benefits company in the United States.

0HG8

US$401.70

7D

-0.06%

1Y

-16.0%

Centene

US$30.5b

Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

0HVB

US$60.47

7D

5.2%

1Y

-18.4%

Kooth

UK£60.0m

Provides digital mental health services to children, young people, and adults in the United Kingdom.

KOO

UK£1.65

7D

1.5%

1Y

-45.2%